What Does the Research Say About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Targeted Risk

If you or someone you know has taken Reglan and developed uncontrollable muscle movements, you may be wondering what the science says about the link. Decades of pharmacovigilance and clinical research have established a clear connection between metoclopramide and tardive dyskinesia. This page reviews the published evidence and regulatory context to help you understand the known risks.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux and diabetic gastroparesis. The FDA-approved labeling includes a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the labeling instructs prescribers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after the drug is discontinued. The labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding treatment for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Risk Factors

The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. Chronic exposure, especially beyond the recommended 12-week limit, increases the risk. The labeling explicitly warns that the risk rises with longer treatment and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD may include lip smacking, grimacing, tongue protrusion, and rapid eye blinking. Diagnosis is based on clinical history and examination, often using standardized rating scales. Regarding the adequacy of warnings, the FDA has required a boxed warning for Reglan since 2009. The warning clearly states the risk of TD, its potential irreversibility, and the importance of limiting treatment duration. However, some patients may have been prescribed Reglan for extended periods without adequate monitoring or warning about TD. The labeling also states that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD continue to occur, often in patients who used the drug for months or years.

Statute of Limitations in Washington

For affected patients in Washington, settlement-related considerations involve the statute of limitations for filing a claim. In Washington, the statute of limitations for personal injury claims, including those related to drug-induced TD, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. This timeline is critical because TD may develop insidiously, and patients may not immediately connect their symptoms to Reglan use. The timeline between exposure and documented harm can vary widely. Some patients develop TD within months, while others may not show symptoms until after years of use. The labeling emphasizes that the risk increases with cumulative exposure, so patients who used Reglan for longer than 12 weeks are at higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Settlement considerations also include the strength of evidence linking the patient's TD to Reglan, the duration and dosage of Reglan use, and whether the prescribing physician provided adequate warnings. Patients who can demonstrate that they were not informed of the TD risk or that they used Reglan beyond the recommended duration may have stronger claims. Medical records documenting the onset of TD symptoms and their temporal relationship to Reglan use are essential. Additionally, the FDA's boxed warning serves as a key piece of evidence that the manufacturer had a duty to warn about TD risks.

Legal and Medical Evaluation

In summary, Reglan carries a known risk of tardive dyskinesia, particularly with prolonged use. The FDA has mandated strong warnings, but cases still arise. Patients in Washington who developed TD after using Reglan should be aware of the three-year statute of limitations and the importance of documenting the timeline of exposure and symptom onset. Legal and medical evaluation is recommended to assess individual circumstances. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to drug-induced tardive dyskinesia, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. It is crucial to act promptly as TD may develop insidiously.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) blocks dopamine D2 receptors in the basal ganglia, leading to supersensitivity of dopamine receptors and involuntary movements. The risk increases with longer treatment duration and higher cumulative doses, as noted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.